Neuraltus Pharmaceuticals, Inc.

Neuraltus Pharmaceuticals, Inc.

Neuraltus Pharmaceuticals, Inc.

Overview
Date Founded

2004

Headquarters

1001 Bayhill Drive,Suite 300,San Bruno, CA 94066

Type of Company

Private

Employees (Worldwide)

1 - 10

Industries

Pharmaceuticals
Hospitals & Patient Services
Holding Companies
Biotechnology

Company Description

Neuraltus Pharmaceuticals, Inc. develops and commercializes molecule therapeutics. It engages in the development of therapeutics to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease as well as inherited metaboloic disorders such as Fabry's disease and Gaucher's disease which also result in neuronal cell death. The company was founded by Michael McGrath, Edgar G. Engleman, and Ari Azhir in 2004 and is headquartered in San Bruno, CA.

Executives & Employees

Chief Executive Officer

President & Chief Operating Officer

Chief Medical Officer

Vice President, Finance

Secretary

Board of Directors

Strategic Advisor at VantagePoint Management, Inc.

Director at ProteinSimple, Inc.

Paths to Neuraltus Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Neuraltus Pharmaceuticals, Inc.
Recent Transactions
Details Hidden

Neuraltus Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Neuraltus Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Neuraltus Pharmaceuticals, Inc. raised money in a private placement transaction

Non-Profit Donations & Grants Received
Investors
Details Hidden

Latterell Venture Partners (LVP) focuses exclusively on investments in large size markets in start-up healthcare companies in the following areas: biotechnology, pharmaceutical, research instrument, biomaterial, medical device and diagnostic ventures. Initial investments range from $50,000 to $10 million, depending on the stage of development of the company's technology or product. LVP expects to support their portfolio companies through financings in the range of $10 million to $20 million per company. The firm leads or co-leads the majority of their investments and typically takes a seat of their portfolio companies' boards of directors.

Details Hidden

VantagePoint Management focuses on investments in the clean technology, information technology and healthcare sectors. Within the clean technology sector, the firm invests mainly in the solar, transportation, energy storage and power management, smart grid, biofuels and water sectors. Within information technology, they tend to invest in the financial technology, Internet/digital media, enterprise solutions and mobile/wireless sectors. VantagePoint healthcare investment include including biotechnology, medical devices and healthcare commerce. In addition, the firm invests in Asia in the clean technology, consumer, healthcare and TMT (technology, media and telecommunications) sectors. Vantage Point invests across a variety of phases of development from start-up through scale-up.

Details Hidden

Founder at Neuraltus Pharmaceuticals, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Neuraltus Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Neuraltus Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Neuraltus Pharmaceuticals, Inc..